5% and 89.7%; P=NS), it was significantly greater in the TDF group for HBeAg-positive patients (78.8% and 50.6%, respectively; P<0.05). Over 48 weeks of treatment, virologic breakthrough occurred in only one patient in each group, and was not associated with emergence Selleckchem GSK1120212 of drug resistance. Univariate and subsequent multivariate logistic regression analyses indicated that TDF was an independent predictor of undetectable HBV DNA at 48 weeks (odds ratio [OR], 3.35; P<0.05), along with cirrhosis (1.61), baseline HBV DNA (0.52), HBeAg positivity (0.22),

age (0.98) and male gender (1.39; Ps<0.05). Conclusions Although TDF and ETV as initial antivirals have similar potency in viral suppression regardless of HBeAg positivity, TDF is superior in achieving HBV DNA negativity after 48 weeks of therapy in HBeAg-positive CHB patients. Longer follow-up data are needed to clarify whether the rapidity of viral suppression by these potent drugs affects ultimate viral clearance. Disclosures: Young-Suk Lim - Advisory Committees or Review Panels: Bayer Healthcare, Gilead Sciences; Grant/Research Support: Bayer Healthcare, BMS, Gilead Sciences, Novartis Han Chu Lee - Grant/Research Support: Medigen Biotechnology Co., Novartis, Roche, Bayer HealthCare, Bristol-Myers Squibb, INC research, Boehringer Ingelheim, Taiho Pharmaceutical

Co., Yuhan Co. The following people have nothing to disclose: Young Joo Yang, Ju Hyun Shim, Hyung-Don Kim, Yeonjung Ha, Mi-Jung Jun, Seung Bum Lee, Jee Eun Yang, Gi-Ae Kim, Eui Ju Park, Jihyun An, Danbi Lee, Kang Mo Kim, Young-Hwa Chung, Selleck AZD9291 Yung Sang Lee,

Dong Jin Suh BACKROUND/AIM: We evaluated the efficacy of tenofovir learn more (TDF)containing treatment and compared the outcome of the TDF monotherapy and TDF with nucleoside analogue (NA) in patients with suboptimal response (SOR) to ADF with or without NA in lamivudine (LMV) resistant CHB. METHODs: All study subjectshave received ADF with or without NAfor more than 6 months due to prior lamivudine resistance and then switched to TDF with or without NA due to SOR (HBV DNA >20 IU/ml after at least 6 months therapy). RESULT: A total of 125 patients were eligible. Previous therapy consisted of either ADF monotherapy(n=18) orADF with NA(LMV, telbivudine, clevudine and entecavir[ETV])(n=107).Overall cumulative proportion of CVR was 100 of 125 (80%) patients at 60 weeks of treatment. Nineof 13 patients (69.2%) with ADFresistance achieved CVR during 48 weeks and ADF mutation didn’t influence to CVR rate (P=0.732). During the follow up period of 48 weeks, Kaplan-Meier analysis showed no significant difference in CVR rate (P=0.706) andrepeated measured ANOVA analysis revealed no difference in the change of viral load (P=0.971)between TDF monotherapyand TDF with NA group. When we compare the patients with partial virologic response (PVR) and with non-response (NR), CVR rate was higher in patients with PVR at 12 weeks (P=0.